Enzyme Replacement Therapy (ert) - Renal Disorders

Relevant Publications

Plasma and platelet lipidome changes in Fabry disease.

Issue Release: 2024

Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.

Issue Release: 2024

Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.

Issue Release: 2024

Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.

Issue Release: 2024

Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy.

Issue Release: 2024

Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.

Issue Release: 2024

Advances in Immune Tolerance Induction in Enzyme Replacement Therapy.

Issue Release: 2024

Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.

Issue Release: 2024

Immobilization of human tyrosine hydroxylase onto magnetic nanoparticles - A novel formulation of a therapeutic enzyme.

Issue Release: 2024

Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis.

Issue Release: 2024

Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report.

Issue Release: 2024

Impact of COVID-19 pandemic on healthcare delivery for lysosomal storage disorders at a tertiary care public hospital in Mumbai.

Issue Release: 2024

Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.

Issue Release: 2024

Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis.

Issue Release: 2024

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).

Issue Release: 2024

Long-term clinical evaluation of patients with alpha-mannosidosis - A multicenter study.

Issue Release: 2024

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.

Issue Release: 2024

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease.

Issue Release: 2024

Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data.

Issue Release: 2024

Diet and Physical Activity in Fabry Disease: A Narrative Review.

Issue Release: 2024

What are the early signs of diabetic nephropathy?

What is Kidney Transplantation?

What are the side effects of ARBs?

What Are the Benefits of Benazepril in CKD?

What Causes ESRD?

What are Some Common ACE Inhibitors Used?

How important is regular monitoring for individuals with diabetes?

Are There Risks Involved?

What is Polycystic Kidney Disease?

What are the Symptoms of ESRD?

Partnered Content Networks

Relevant Topics